¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º ZHWxU  
'Cv>V"X: `  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ o N\IQ7oI  
&O:IRR7p  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) &P@dx=6d  
b-+~D9U <  
1. ICAM-1 pmIOV~K  
7^2  
2. interleukin 12(IL-12) QQPT=_P]  
PXRkK63  
3. tumor infiltrating lymphocyte )#H&lH  
YXi'^GU@  
4. TCR/CD3 complex +'ZJ]  
WP5QA8`3  
5. hematopoietin receptor family `Q@w*ta)  
5vmc'Om  
6. individual idiotype(IdI) r+D ?_Lk  
]2 7  
7. integrin cR *5iqA  
.S{FEV  
8. colony-stimulatory factor (CSF) J_|LG rt})  
O?=YY@j  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© %2;Nj; J$  
4!</JZX~$  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? ^c-8~r|y,  
I""zg^Rq  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ )/y7Fh  
y v58~w*"  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ^5D%)@~  
JqmxS*_P  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 9 zL(PkC%\  
}mYxI^n  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) =] +owl2  
v:1DNR4  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ _t/~C*=:=  
?]AF? 0/  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) gJZH??b  
zCe[+F  
3. immunoglobulin superfamily (IgSF) RD|DHio %  
N;q)r  
4. selectin *8I"7'xh  
WqJrDj~  
5. anti-idiotypic antibody (¦ÁId) Xk hGU?={  
0g`$ Dap  
6. major histocompatibility complex(MHC) i,B<k 0W9  
M-8 `zA2  
7. immunotolerance /os,s[w  
+WjX@rSq[  
8. biological reponse modifier(BRM) nCS" l5  
oMNSQMlI  
9. immune reponse gene (Ir gene) &\y`9QpVF  
^~;"$=Wf  
10. reshaped antibody (or reconstituted antibody) cSTF$62E  
yu>o7ie+;Y  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© *>h|<|T'  
4Ql9V M%y  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ni85Ne$  
}a%1$>sj  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? _CMNmmp`e  
Yi j^hs@eV  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ ALQ-aXJ  
E)`:sSd9  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? v!W{j&N  
1\a.o[g3e  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ #g/m^8n?s  
ob;O,&e0>  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? O 6ph_$nt.  
?t5<S]'r$  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ HbRv U}C1  
r )HZaq  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ .8->n aj|  
)8!*,e=4  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? {- &`@V  
O0FUJGuTS  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ]q~bi<E9W  
$A`m8?bY  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: W4,'?o  
~yt7L,OQ  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: @C<ofg3E  
v;`>pCal  
ÃâÒßѧ tY>Zy1hlI  
qX*xQA|ak,  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 2]<.m]  
Ta[\BWR2  
1. CD8 C5~n^I|  
g60k R7;\  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) DJ DQH\&  
qvLh7]sbK:  
3. immunoglobulin fold(Ig fold) M\/hK2J# #  
uIbAlE  
4. cadherin (Ca-dependent cell adhesion moleculers) q-+:1E  
0-[naGz  
5. idiotype-anti-idiotypic antibody immune network theory ,zdGY]$  
lm 96:S  
6. HLA class II antigen Aj|->Y  
33EF/k3vW  
7. complementarity-determining region (CDR) J jm={+@+  
.>eRX%  
8. perforin(or pore-forming protein ,PFP) P1Z"}Qw  
k #zDY*kj  
9. high affinity IL-2 receptor n| {#5#  
v2E<~/|  
10. artificial active immunization *g,ls(r\[  
Z[OX {_2]K  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 0F@~[W|2  
FGx) ?  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠmf3,V|>[\  
u\Ylo.)b  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 H 7GI`3o  
KCW2 UyE]  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ 4hy -M>!D|  
|67Jw2  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ zQ |2D*W  
J?w_DQa  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 3fhY+$tq  
+7}^Y}(  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Jgv Mx  
o 2 Nu@^+  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 8Y.q P"s  
ea"X$ <s>-  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ | J3'#7  
wn5OgXxG<  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ x[)-h/&Fh  
} +}nrJv  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 1H-Y3G>jN  
Q3 8+`EhLA  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Tse#{  
; R}>SS'  
1. immunoglobulin gene rearrangement Eo6N'h>h  
`/PBZnj  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) s#s">hMrI  
*'-4%7C`1  
3. flow cytometry(FCM) bgi_QB#k\  
N l@G\_  
4. carrier effect 9jTBLp-i#N  
wuH*a3(  
5. positive selection of T lymphocytes in thymus MW 7~=T  
!0,q[|m  
6. mouse TH1(Th1) and TH2(Th2) subsets >K9Ia4I,  
>J7slDRo  
7. perforin (pore-forming protein ,PFP) lV$JCNe  
[=>=5'-  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) ,p d -hu  
:hZM$4  
9. SH-2(src-homology region 2) Kz"3ba}KH  
?:\/-y)Sp  
10. Ab2¦Â (internal image) Hh1_zd|  
^aSb~lce  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 9>~pA]j%  
`j>5W<5q\  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? L+8ar9es  
Me .I>7c  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? $X#y9<b W  
IEhD5?  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ.g8*K "  
b(0<,r8  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ZM.'W}J{ *  
zKd@Ab  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠCPOH qK`k  
zV&l^.  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) `MU~N_  
.?45:Ey~g  
ÃâÒßѧרҵ£º NI s7v  
D~C'1C&W  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ (.4lsKN<  
Vf cIR(  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? \4N8-GwZQ  
x"b'Pmw  
´«È¾²¡Ñ§×¨Òµ£º C8-7XQ=B:b  
cXb*d|-|N  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 4,)9@-|0R  
]DNPG"  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ b}K,wAx  
-Uo11'{  
Ïû»¯×¨Òµ£º ` g]  
yNvAT>H  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ 4m0^ N  
%66="1z0@  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ?  cyl%p$  
;u<Ah?w=Z  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ *JJ8\R&P0  
?%6oM  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1iF=~@Nz_  
0ID9=:J  
1. Fas(CD95)/FasL k'o[iKlu  
GLf!i1Z  
2. common chain of cytokine receptor \Bo$ 3  
 V9) /  
3 . TCR/CD3 complex '[ #y|  
]RT  
4. negaive selection of thymocytes wKM9fs  
>PA*L(Dh%  
5. artificial active immune G&*P*f1 S  
nm5DNpHk  
6. anti-idiotypic pCE GZV,d@  
O) q4^AE$  
7. IgSF .y s_'F-]0  
t.( `$  
8. Integrin E;a,].  
[D~]  
9. chemokine 30sJ"hF9  
NVMn7H}>  
10. B7/CD28 [BE_^d5&  
:BPgDLL,  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© a&%aads  
ps<E f  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ 0f@+o}i=)  
U"r*kO %  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ g7zl5^o3j  
)-4c@  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ D)PX|xrn  
}h^ fX  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ v[ iJ(C_  
C'I&<  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 0S5xmEzop  
(9u`(|x  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ q9vND[BQ  
b\"F6TF:  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© NMkP#s7.y  
x"z\d,O%W  
1. B7/CD28 J&aN6l?  
gCg hWg{S  
2. Th1 subset ZjxF@`H  
5ngs1ZF@  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ={B C0,  
#2^0z`-\_z  
4. antibody affinity maturation Qf_N,Bq{a  
(1CP]5W  
5. AP-1 fn<dr(Dx  
/H<{p$Wd  
6. single chain variable fragment£¨ScFv£© 1`?o#w  
;!HQ!#B  
7. NK cell receptor Hdyl]q-(P  
RJ?)O#}  
8. Zinkernagel-Doherty phenomenon Q9cSrU[$  
GSRf/::I}4  
9. Ig fold 5 SQ!^1R 9  
sO ) H#G  
10. CD40/CD40L 1HO;~NJ]m  
UwW@}cy,L  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© h>V6}(~;.  
c7+6[y DVE  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ )y] Dmm  
al#(<4sJ  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 2}<tzDI'  
6OE x An8  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ pq0Z<b;2  
ir'<H<t2  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 6`2i'flv  
qVU<jt  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ \:h7,[e  
lfBCzxifC  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ pOK=o$1V8  
1o5kP,)  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ ~d&&\EZ  
$-DW+|p.?^  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© w5q6c%VZ  
MNU7O X<  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© VP< zOk7  
ecm+33C  
1.Co-stimulators (or co-stimulating molecules) iM!V4Wih6  
V@+sNM  
2.NK-kB XSx!11  
&5jc &CS  
3.Immunoglobulin superfamily R)d_0Ng  
dDiy_Q6  
4.antigen-presenting cell (APC) &T-:`(  
xe OfofC(l  
5.death domain {B=64,D^7R  
`!N.1RP _  
6.CCR and CXCR -DGuaUU  
q: F6MW  
7.Lectin (or mitogen) rG-x 3>b  
(xfy?N  
8.Clusters of differentiation, CD) `0s3to% 7  
Nba1!5:M  
9.B7 family r *N@%T  
NW wKp?  
10.Cytotoxic T lymphocyte, CTL) 9XUYy2{G  
%N\45nYU:  
11.IL-15 and IL-15 receptor (IL-15R) ='I2&I,)  
ko!]vHB9`  
12.MHC restriction ! j6CvclT  
n%2c<@p#  
13.Affinity-chromatography sNG 7fi.|  
&6GW9pl[  
14.Cyctosprin A, CsA m,5m'9 dj  
/.mx\_$   
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) Hm 0;[i  
L.9@rwfI  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© gBgaVG  
2zsDb'r  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 7CU<R9Kl  
'eQ*?a43  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ @ uL4'@Ej  
[ 2!?pVI  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ fn//j7 j  
lR ZuXo9<  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ){J,Z*&  
qpB8ujj<V  
ÃâÒßѧרҵ£º /KgP<2p  
CTB qX  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ "f!H[F1~  
jjoyMg95  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ R4f_Kio  
xCU pMB7  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ X5)].[d  
@vi;P ^1!  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) p?<T _9e  
:N=S nyz  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) U7xQ 5lph  
.gwT?O,  
1. ADCC(antibody dependent cell-mediated cytotoxicity) >` |sBx  
4^w`] m  
2. »·æß¾úËØ(cyclosporin) K"=I,Vr:  
=.q8*7UY  
3. KIR(killer cell inhibitory receptor) D14i]   
Z&Z= 24q_  
4. HLDA(human leucocyte differentiation antigen) "&TN}SBW  
/80RO:'7  
5. Interleukin 18(IL-18) =(as{,j  
!-|{B3"6  
6. ÕûºÏËØ(integrin) &n2dL->*#  
p M_oIH'8:  
7. Fas/FasL .^FdO$"  
IaYy5Rw  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) "D/\&1.&  
qa)Qf,`  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) %1PNP<3r0  
{$qLMx';  
10. Th1/Th2 ,mvU`>Ry  
Jbqm?Fy4X  
11. »ùÒòÒßÃç(DNAÒßÃç) wD`jks  
`RL n)a  
12. chemokines and chemokine receptor  <sC.  
<lHVch"(^$  
13. ÃâÒßÄÍÊÜ :x@j)&  
S,2{^X  
14. ¹²´Ì¼¤·Ö×Ó . KzU7  
tFYo d#  
15. ËÀÍö½á¹¹Óò(death domain) IO]%AL(.;  
/.%AE|0+X  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) H.]rH,8  
qK12:  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 8k -l`O~  
^+'\ u;\  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ_ -C{:rV  
K&>+<bJ_  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î Avn)%9  
FJ(}@U}57  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ tg' 2 v/  
a\?-uJ+  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå SdQ"S-H  
[,As;a*o  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ Bi$nYV)-l  
2 rx``,7Q  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) brt1Kvu8(  
Rt2<F-gY  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£  pu?D^h9/  
6y+}=)J  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ eY#_!{*Wn  
Q% LQP!Kg  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»